@willkidney + @kevin_damman bring the heart of nephrology to the heart of Munich
#StampOnCKD@escardio@MarkusAtHome
Test for CKD in all ❤️ patients
Provide Nephroprotective Therapy
Give iv CM whenever needed
Prefer DOAC over VKA for most CKD pat
Fresh off the press at #ScientificSessions26! 🚨
Our OPTIMAL-DIABETES trial is officially published in @NEJM. In patients with type 2 diabetes and high cardiovascular risk, intensive therapy targeting a systolic blood pressure below 120 mm Hg did not significantly reduce major cardiovascular events compared to the standard <140 mm Hg target. 📊
Read the full manuscript here:
🔗 nej.md/3UZYKCy
@AHAScience#Diabetes#Hypertension#CardioTwitter#MedX
The focused update of the KDIGO 2027 CKD Guideline is available for public review through November 4, 2026.
KDIGO invites the global kidney community to review the draft and share feedback to help inform and improve the final update.
Visit the KDIGO CKD Guideline website to download the draft and share your comments via the feedback survey:
kdigo.org/guidelines/ckd-eva…
The focused update addresses new evidence since publication of the KDIGO 2024 CKD Guideline on SGLT2 inhibitors, GLP-1-based therapies, and nsMRAs in people with CKD, excluding those receiving dialysis or who have received a kidney transplant.
Thank you for your time and insights.
Have a read - this is a kidney example, but there may be much wider implications if we start applying polygenic risk scores developed in general populations to populations with disease. Results could be qualitatively completely misleading in patients with prevalent disease…
Now open access in @NDTsocial@willkidney
Impact of selection bias on the association of kidney function polygenic scores with CKD progression
🧐Using PGS in populations selected for prevalent disease may lead to misleading conclusions
▶️academic.oup.com/ndt/article…
Did you catch Prof Will Herrington's talk on 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease at #ESCCongress? The guidelines were published earlier today with @escardio and European Renal Association (ERA) ➡️ academic.oup.com/eurheartj/a…
🚨 First ESC guideline dedicated to CVD + CKD at #ESCCongress.
The key message:
CKD should actively change cardiovascular management, not simply appear on the problem list.
New STAMP on CKD framework:
Screen
Triage
Address CKD risk
Modify CVD management
Plan care
Major practical points:
🔹 Screen ALL patients with CVD using eGFR + albuminuria
🔹 SBP target 120-129 mmHg if tolerated when eGFR ≥30
🔹 ACEI/ARB + SGLT2i for most appropriate CKD patients
🔹 SGLT2i can be initiated at eGFR ≥20
🔹 Finerenone and GLP-1RA gain important roles in diabetic CKD
🔹 HF + CKD: SGLT2i irrespective of LVEF, with more aggressive decongestion when diuretic resistance develops
🔹 And an important clinical reminder:
Kidney disease should not unnecessarily delay cardiovascular investigation or intervention.
Treat the cardiorenal patient as one physiology, not two separate organs.
@escardio@ERAkidney@ESC_Journals@willkidney@kevin_damman#CKD#Cardiorenal#HeartFailure
@willkidney + @kevin_damman bring the heart of nephrology to the heart of Munich
#StampOnCKD@escardio@MarkusAtHome
Test for CKD in all ❤️ patients
Provide Nephroprotective Therapy
Give iv CM whenever needed
Prefer DOAC over VKA for most CKD pat
🎉EASi-KIDNEY has recruited 7000 randomised participants!
📉EASi-KIDNEY will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD) ➡️ buff.ly/qXd6j1S
Today: EASi-KIDNEY=6609 participants=EMPA-KIDNEY! Brilliant patients, clinics and hospitals from 500+ sites are growing larger renal trials & wider collaborations. 🙏 🙏 🙏 🤩 Just a few more thousand volunteers patients needed…..
🎉EASi-KIDNEY has recruited 6000 randomised participants!
📉EASi-KIDNEY will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD) ➡️buff.ly/qXd6j1S
Now open access in @NDTsocial
UACR and UPCR with kidney failure: a pooled analysis of clinical trials
🧐UACR and UPCR are robust predictors of kidney failure, but UACR has stronger associations, particularly in CKD+diabetes.
▶️academic.oup.com/ndt/article…